



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life-improving drugs. For more than 30 years, we've been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in over 100 countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug development process.

We help change people's lives for the better every single day. It's what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$71.50
Change (%)	▲ 0.13 (0.18%)
Volume	124,481
52 Week Low	\$39.52
Market Cap	\$4,458,606,228
Rolling EPS	1.69
PE Ratio	42.2555
Shares Outstanding	62,471,714
Data as of 05/24/17 4:00 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

05/22/17	PRA Health Sciences Named International Clinical Research Company of the Year
05/04/17	PRA Health Sciences Announces The Center for Pediatric Clinical Development
05/02/17	PRA Health Sciences Named Clinical Research Company of the Year

## SEC FILINGS

Filing Date	Form
04/26/17	10-Q
04/25/17	8-K
04/21/17	DEFA14A
04/21/17	DEF 14A

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Ali J. Satvat	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)